Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: follow-up analysis from the randomized ‘FIRST’ study

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Breast Cancer Research and Treatment

• Publication date

  2012-10-13

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s10549-012-2192-4PMID 23065000
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Fulvestrant revisited: efficacy and safety of the 500-mg dose.

  2011cited by this paper
• Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer.

  2010cited by this paper
• Results of a phase II study comparing three dosing regimens of fulvestrant in postmenopausal women with advanced breast cancer (FINDER2)

  2010cited by this paper
• Three dose regimens of fulvestrant in postmenopausal Japanese women with advanced breast cancer: results from a double-blind, phase II comparative study (FINDER1).

  2010cited by this paper
• Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST study.

  2009cited by this paper
• Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group.

  2008cited by this paper
• Fulvestrant (Faslodex) -- how to make a good drug better.

  2007cited by this paper
• Sensitivity to further endocrine therapy is retained following progression on first-line fulvestrant

  2005cited by this paper
• Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial.

  2004cited by this paper
• Pharmacokinetic Profile of Intramuscular Fulvestrant in Advanced Breast Cancer

  2004cited by this paper
• Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group.

  2003cited by this paper
• Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women

  2003cited by this paper
• Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment.

  2002cited by this paper
• Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial.

  2002cited by this paper
• Anastrozole Is Superior to Tamoxifen as First-Line Therapy in Hormone Receptor Positive Advanced Breast Carcinoma Results of Two Randomized Trials Designed for Combined Analysis

  2001cited by this paper
• Anastrozole is superior to tamoxifen as first‐line therapy in hormone receptor positive advanced breast carcinoma

  2001cited by this paper
• Comparison of the Short-Term Biological Effects of 7α-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)-nonyl]estra-1,3,5, (10)-triene-3,17β-diol (Faslodex) versus Tamoxifen in Postmenopausal Women with Primary Breast Cancer

  2001cited by this paper
• Comparison of the short-term biological effects of 7alpha-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)-nonyl]estra-1,3,5, (10)-triene-3,17beta-diol (Faslodex) versus tamoxifen in postmenopausal women with primary breast cancer.

  2001cited by this paper
• New guidelines to evaluate the response to treatment in solid tumors

  2000cited by this paper
• Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group.

  2000cited by this paper
• Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study.

  2000cited by this paper
• New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

  2000influential reference
• A potent specific pure antiestrogen with clinical potential.

  1991cited by this paper

• Identification of a Muscle-Invasive Bladder Carcinoma Molecular Subtype of Poor Responders to Neoadjuvant Chemotherapy and High Expression of Targetable Biomarkers

  2026cites this paper
• Open‐Label Study Assessing Relative and Absolute Bioavailability of Oral Camizestrant Formulations and Food Effects in Healthy Postmenopausal Women

  2026cites this paper
• Disposition and Absolute Bioavailability of Oral Imlunestrant in Healthy Women: A Phase 1, Open‐Label Study

  2025cites this paper
• Recurrent Hormone Receptor–Positive Breast Cancer With Multiple Sites of Distant Metastasis: A Case Report and Review of the Literature

  2025cites this paper
• Effectiveness of Hormonal Therapy for Post-Menopausal Women with Hormone Receptor-Positive Advanced Breast Cancer: A Systematic Review and Meta-Analysis of Clinical Trials

  2025cites this paper
• Fulvestrant in the treatment of luminal HER-2-negative metastatic breast cancer

  2025cites this paper
• Camizestrant, a next-generation oral SERD, versus fulvestrant in post-menopausal women with oestrogen receptor-positive, HER2-negative advanced breast cancer (SERENA-2): a multi-dose, open-label, randomised, phase 2 trial.

  2024cites this paper
• First‑line endocrine therapy for hormone receptor positive and HER‑2 negative metastatic breast cancer: A Bayesian network meta‑analysis

  2024cites this paper
• Recent progress of CDK4/6 inhibitors’ current practice in breast cancer

  2024cites this paper
• Next generation selective estrogen receptor degraders in postmenopausal women with advanced-stage hormone receptors-positive, HER2-negative breast cancer

  2024cites this paper
• Fulvestrant plus vandetanib versus placebo for the treatment of patients with metastatic breast cancer resistant to aromatase inhibitor therapy (FURVA): a multicentre, Phase 2, randomised controlled trial

  2023cites this paper
• A retrospective, non-interventional study of breast cancer patients diagnosed with ER+/HER2 negative, locally advanced or metastatic breast cancer treated with palbociclib in Denmark

  2023cites this paper
• Systemic therapy for hormone receptor‐positive/human epidermal growth factor receptor 2‐negative early stage and metastatic breast cancer

  2023cites this paper
• Targeted co-delivery of daunorubicin and cytarabine based on the hyaluronic acid prodrug modified liposomes

  2022cites this paper
• Endocrine Therapy-Based Strategies for Metastatic Breast Cancer with Different Endocrine Sensitivity Statuses: A Systematic Review and Network Meta-Analysis

  2022cites this paper
• Optimizing CDK4/6 inhibitors in advanced HR+/HER2- breast cancer: a personalized approach.

  2022cites this paper
• Oral Selective Estrogen Receptor Degraders (SERDs) in Breast Cancer: Advances, Challenges, and Current Status

  2022cites this paper
• Oral Selective Estrogen Receptor Degraders (SERDs) in Breast Cancer: Advances, Challenges, and Current Status

  2022cites this paper
• Estrogen Receptor Bio-Activities Determine Clinical Endocrine Treatment Options in Estrogen Receptor-Positive Breast Cancer

  2022cites this paper
• Endocrine therapy leads the first- and second-line treatment options for hormone receptor-positive advanced breast cancer—comments on the Monarch plus study

  2022cites this paper
• Real-world data of fulvestrant as first-line treatment of postmenopausal women with estrogen receptor-positive metastatic breast cancer

  2021cites this paper
• Meta-analyses of visceral versus non-visceral metastatic hormone receptor-positive breast cancer treated by endocrine monotherapies

  2021cites this paper
• Meta-analyses of phase 3 randomised controlled trials of third generation aromatase inhibitors versus tamoxifen as first-line endocrine therapy in postmenopausal women with hormone receptor-positive advanced breast cancer.

  2021cites this paper
• Meta-analyses of visceral versus non-visceral metastatic hormone receptor-positive breast cancer treated by endocrine monotherapies

  2021cites this paper
• Management of hormone receptor–positive, human epidermal growth factor 2–negative metastatic breast cancer

  2021cites this paper
• Landmark trials in the medical oncology management of metastatic breast cancer.

  2021cites this paper
• Cost-effectiveness of ribociclib plus letrozole versus palbociclib plus letrozole or letrozole as monotherapy in first-line treatment of postmenopausal women with HR+/HER2− locally advanced or metastatic breast cancer: a Brazilian private payer perspective

  2021cites this paper
• Endocrine-Based Treatments in Clinically-Relevant Subgroups of Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Systematic Review and Meta-Analysis

  2021cites this paper
• Breast cancer liver metastasis: current and future treatment approaches

  2021cites this paper
• Phase Ib Study of the Oral Proteasome Inhibitor Ixazomib (MLN9708) and Fulvestrant in Advanced ER+ Breast Cancer Progressing on Fulvestrant

  2021cites this paper
• Phase Ib Study of the Oral Proteasome Inhibitor Ixazomib (MLN9708) and Fulvestrant in Advanced ER+ Breast Cancer Progressing on Fulvestrant.

  2021cites this paper
• The Japanese Breast Cancer Society Clinical Practice Guidelines for systemic treatment of breast cancer, 2018 edition

  2020cites this paper
• The Predictive Value of Early Changes in F-Fluoroestradiol Positron Emission Tomography/Computed Tomography During Fulvestrant 500 mg Therapy in Patients with Estrogen Receptor-Positive Metastatic Breast Cancer

  2020cites this paper
• Clinical Challenges in the Management of Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: A Literature Review

  2020cites this paper
• Fulvestrant in the treatment of luminal metastatic breast cancer: the balance of effectiveness and safety

  2020cites this paper
• Clinical aspects of the use of ribociclib

  2020cites this paper
• Efficacy and Safety of Fulvestrant 500mg in Hormone-receptor Positive Human Epidermal Receptor 2 Negative Advanced Breast Cancer: A Real-world Study in China

  2020cites this paper
• Chinese expert consensus on the clinical diagnosis and treatment of advanced breast cancer (2018)

  2020cites this paper
• Endocrine therapy combined with targeted therapy in hormone receptor-positive metastatic breast cancer

  2020cites this paper
• Endocrine-Resistant Breast Cancer: Mechanisms and Treatment

  2020cites this paper
• The Exceptional Responders Initiative: Feasibility of A National Cancer Institute Pilot Study.

  2020cites this paper
• The Predictive Value of Early Changes in 18 F-Fluoroestradiol Positron Emission Tomography/Computed Tomography During Fulvestrant 500 mg Therapy in Patients with Estrogen Receptor-Positive Metastatic Breast Cancer.

  2020cites this paper
• Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology.

  2020cites this paper
• Real‐world effectiveness of fulvestrant monotherapy as first endocrine treatment in patients with metastatic breast cancer

  2020cites this paper
• First-line endocrine therapy for postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer: a systematic review and meta-analysis

  2020cites this paper
• GLL398, an oral selective estrogen receptor degrader (SERD), blocks tumor growth in xenograft breast cancer models

  2020cites this paper
• CDK4/6 inhibitors in breast cancer – from in vitro models to clinical trials

  2020cites this paper
• Clinical Development

  2019cites this paper
• Hormone-Responsive Cancers

  2019cites this paper
• Comparative Efficacy of CDK4/6 Inhibitors Plus Aromatase Inhibitors Versus Fulvestrant for the First-Line Treatment of Hormone Receptor-Positive Advanced Breast Cancer: A Network Meta-Analysis

  2019cites this paper
• Fulvestrant in the treatment of hormone receptor‐positive/human epidermal growth factor receptor 2‐negative advanced breast cancer: A review

  2019cites this paper
• Cost-Effectiveness Analysis of Fulvestrant 500 mg in Endocrine Therapy-Naïve Postmenopausal Women with Hormone Receptor-Positive Advanced Breast Cancer in the UK

  2019cites this paper
• A meta-analysis of clinical benefit rates for fulvestrant 500 mg vs. alternative endocrine therapies for hormone receptor-positive advanced breast cancer

  2019cites this paper
• Patterns of treatment and outcome with 500-mg fulvestrant in postmenopausal women with hormone receptor-positive/HER2-negative metastatic breast cancer: a real-life multicenter Italian experience

  2019cites this paper
• The 'dark side' of tamoxifen : understanding adverse cellular response to endocrine therapy in ER+ breast cancer

  2019cites this paper
• Altered Steroid Milieu in AI-Resistant Breast Cancer Facilitates AR Mediated Gene-Expression Associated with Poor Response to Therapy

  2019cites this paper
• Metastatic breast cancer patients with lung or liver metastases should be distinguished before being treated with fulvestrant

  2019cites this paper
• Advances in Endocrine-Based Therapies for Estrogen Receptor-Positive Metastatic Breast Cancer

  2019cites this paper
• NCCN CLINICAL PRACTICE GUIDELINES IN ONCOLOGY

  2019cites this paper
• A Single-centre, Retrospective, Observational Analysis of Fulvestrant for Recurrent/metastatic Breast Cancer According to Metastatic Site

  2019cites this paper
• Pharmacokinetic and pharmacodynamic analysis of fulvestrant in preclinical models of breast cancer to assess the importance of its estrogen receptor-α degrader activity in antitumor efficacy

  2019cites this paper
• Expanding Treatment Arsenal for Oestrogen Receptor – Positive Human Epidermal Growth Factor Receptor 2 – Negative Metastatic Breast Cancer

  2019cites this paper
• Use of Novel Combination Therapies in the Treatment of Advanced HR+/HER2- Breast Cancer.

  2018cites this paper
• ZB716, a steroidal selective estrogen receptor degrader (SERD), is orally efficacious in blocking tumor growth in mouse xenograft models

  2018cites this paper
• First-line vs second-line fulvestrant for hormone receptor-positive advanced breast cancer: A post-hoc analysis of the CONFIRM study.

  2018cites this paper
• Acquired resistance to aromatase inhibitors: where we stand!

  2018cites this paper
• RE: "Cost-effectiveness analysis of fulvestrant versus anastrozole as first-line treatment for hormone receptor-positive advanced breast cancer," by Ding H., et al.

  2018cites this paper
• Current Strategies of Endocrine Therapy in Elderly Patients with Breast Cancer

  2018cites this paper
• An update on treatment for post-menopausal metastatic breast cancer in elderly patients

  2018cites this paper
• Health-related quality of life from the FALCON phase III randomised trial of fulvestrant 500 mg versus anastrozole for hormone receptor-positive advanced breast cancer.

  2018cites this paper
• Progression-free survival results in postmenopausal Asian women: subgroup analysis from a phase III randomized trial of fulvestrant 500 mg vs anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON)

  2018cites this paper
• Fulvestrant for the treatment of advanced breast cancer

  2018cites this paper
• Effect of first-line endocrine therapy in patients with hormone-sensitive advanced breast cancer: a network meta-analysis

  2018cites this paper
• Efficacy of fulvestrant in the treatment of postmenopausal women with endocrine-resistant advanced breast cancer in routine clinical practice

  2018cites this paper
• Fulvestrant in management of hormone receptor-positive metastatic breast cancer.

  2018cites this paper
• Advances in Endocrine Therapy for Postmenopausal Metastatic Breast Cancer.

  2018cites this paper
• Overcoming endocrine resistance in metastatic hormone receptor-positive breast cancer

  2018cites this paper
• Hormone receptor-positive, HER2-negative metastatic breast cancer: redrawing the lines.

  2018cites this paper
• Current Landscape of Targeted Therapies for Hormone-Receptor Positive, HER2 Negative Metastatic Breast Cancer

  2018cites this paper
• Clinical utility of fulvestrant in the treatment of breast cancer: a report on the emerging clinical evidence

  2018cites this paper
• Fulvestrant plus goserelin versus anastrozole plus goserelin versus goserelin alone for hormone receptor-positive, HER2-negative tamoxifen-pretreated premenopausal women with recurrent or metastatic breast cancer (KCSG BR10-04): a multicentre, open-label, three-arm, randomised phase II trial (FLAG s

  2018cites this paper
• Fulvestrant for Untreated Hormone-Receptor Positive Locally Advanced or Metastatic Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

  2018cites this paper
• Optimizing treatment-sequencing strategies for the management of postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer: A Malaysian perspective

  2018cites this paper
• Breast Cancer, Including Brief Discussion of Male Breast Cancer

  2018cites this paper
• Cyclin-dependent kinase (CDK) inhibitors for hormone receptor-positive advanced breast cancer

  2018cites this paper
• Endocrine Therapy of Metastatic Breast Cancer

  2018cites this paper
• Informe de Posicionamiento Terapéutico de palbociclib (Ibrance®) en cáncer de mama

  2018cites this paper
• Hypoxia-induced switch in SNAT2/SLC38A2 regulation generates endocrine-resistance in breast cancer

  2018influential citation
• Is There Still a Role for First-Line Single Agent Endocrine Therapy in HR+ and HER2- Advanced Breast Cancer

  2017cites this paper
• Mechanisms of resistance to selective estrogen receptor down-regulator in metastatic breast cancer.

  2017cites this paper
• Patient Case Lessons: Endocrine Management of Advanced Breast Cancer

  2017cites this paper
• Systematic review and network meta-analysis comparing palbociclib with chemotherapy agents for the treatment of postmenopausal women with HR-positive and HER2-negative advanced/metastatic breast cancer

  2017cites this paper
• New agents for the management of resistant metastatic breast cancer

  2017cites this paper
• NCCN Guidelines Insights: Breast Cancer, Version 1.2017.

  2017cites this paper
• Treatment patterns and real world clinical outcomes in ER+/HER2- post-menopausal metastatic breast cancer patients in the United States

  2017cites this paper
• Selective estrogen receptor modulators (SERMs) and selective estrogen receptor degraders (SERDs) in cancer treatment.

  2017cites this paper
• Hormone Therapy for Metastatic Breast Cancer

  2017cites this paper
• Metastatic breast cancer: Endocrine therapy landscape reshaped

  2017cites this paper
• Cost‐effectiveness analysis of fulvestrant versus anastrozole as first‐line treatment for hormone receptor‐positive advanced breast cancer

  2017cites this paper
• Fulvestrant in advanced breast cancer: evidence to date and place in therapy

  2017cites this paper